Elevated polyadenylated histone gene transcription in human cancer
Abstract
Histone production is tightly restricted to S-phase to prevent genomic instability, yet human cancers with an overabundance of RNA Polymerase II (RNAPII) at histone genes are associated with aggressive cancers. To better understand histone gene overexpression in cancer, we applied a quantitative PCR assay to measure total replication-coupled histone output across the histone gene clusters using cell line models. We observed pervasive accumulation of polyadenylated histone transcripts, supported by analysis of >1,400 RNA-sequencing datasets in human cancers, with more than 70% of patients showing tumor specific increases. This alternative processing preferentially enriches for histone H2B, which lacks replication independent variants, across >8,300 tumors comprising diverse cancer types and transcriptional subtypes. We also found that disruption of nuclear components required to maintain RNAPII levels at the histone genes increased polyadenylated histone transcripts. Our results suggest that S-phase-dependent histone genes are subject to unscheduled gap phase transcription in human cancer.
Related
- DDX3x Regulates NINJ1 Transcription via Histone Lactylation in Sepsis Associated‐Acute Kidney Injury
- Case Report: Prostatic infarction mimicking prostate cancer in a patient with markedly elevated prostate-specific antigen
- A low-androgen environment sustains redox-active sGC states required to restrain castration-resistant prostate cancer growth via elevated cGMP levels
- Genome-wide CRISPR-screening identifies p53 as regulator of cancer cell sensitivity to the histone evicting anthracycline aclarubicin.
- Non-histone protein L-lactylation in cancer: a metabolic switch for immune evasion and therapeutic resistance.
BibTeX
@misc{paranal2026elevated,
title = {{Elevated polyadenylated histone gene transcription in human cancer}},
author = {Ronald M. Paranal and Terri D. Bryson and Guillermina Rios Rios and Kevin K. Nguyen and Kami Ahmad and Steven Henikoff},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.758961},
url = {https://www.biorxiv.org/content/10.64898/2026.10.14.758961v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Elevated polyadenylated histone gene transcription in human cancer
AU - Ronald M. Paranal
AU - Terri D. Bryson
AU - Guillermina Rios Rios
AU - Kevin K. Nguyen
AU - Kami Ahmad
AU - Steven Henikoff
PY - 2026
DA - 2026/10/14
PB - bioRxiv
DO - 10.64898/2026.10.14.758961
UR - https://www.biorxiv.org/content/10.64898/2026.10.14.758961v1
AB - Histone production is tightly restricted to S-phase to prevent genomic instability, yet human cancers with an overabundance of RNA Polymerase II (RNAPII) at histone genes are associated with aggressive cancers. To better understand histone gene overexpression in cancer, we applied a quantitative PCR assay to measure total replication-coupled histone output across the histone gene clusters using cell line models. We observed pervasive accumulation of polyadenylated histone transcripts, supported by analysis of >1,400 RNA-sequencing datasets in human cancers, with more than 70% of patients showing tumor specific increases. This alternative processing preferentially enriches for histone H2B, which lacks replication independent variants, across >8,300 tumors comprising diverse cancer types and transcriptional subtypes. We also found that disruption of nuclear components required to maintain RNAPII levels at the histone genes increased polyadenylated histone transcripts. Our results suggest that S-phase-dependent histone genes are subject to unscheduled gap phase transcription in human cancer.
SN - 2692-8205
ER -